Overview
Global pharma major Lupin Limited (Lupin) announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (FDA) for its manufacturing facility in Somerset, New Jersey, with a Voluntary Action Indicated (VAI) status.
Previous inspection- The facility was inspected from May 7 to May 17, 2024.
Words from MD: Lupin
“We are very pleased to have received the EIR with a satisfactory VAI status for our Somerset facility. This is a significant milestone in building our reputation of being best-in-class in quality and compliance,” said Nilesh Gupta, managing director, Lupin.
About Lupin
- Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.
- The company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the US, India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
